Version history

{
  "session_id": "sess_SDA-2026-04-07-gap-pubmed-20260406-062150-a6cc7467_task_9aae8fc5",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "scidex.core.llm.complete",
  "action": "propose",
  "content": "# Therapeutic Hypotheses: Trehalose-Induced LMP and Paradoxical Autophagy Enhancement\n\n---\n\n## Hypothesis 1: Limited Calcium Release Without Sufficient Cathepsin Efflux\n\n**Mechanism:** Trehalose induces selective lysosomal permeabilization that preferentially releases Ca²⁺ without complete cathepsin efflux. Lysosomal Ca²⁺ release activates calcineurin, leading to TFEB nuclear translocation and autophagy gene transcription, while insufficient cytosolic cathepsin activity fails to trigger apoptotic cascades.\n\n**Target:** Lysosomal calcium channel (MCOLN1/TRPML1), calcineurin/NFAT pathway\n\n**Supporting Evidence:**\n- TRPML1-mediated lysosomal Ca²⁺ release activates calcineurin and TFEB nuclear translocation (PMID: 27807044)\n- Partial LMP preferentially releases small molecules (Ca²⁺, ATP) before larger hydrolases (PMID: 23645775)\n- Trehalose osmotic effects may selectively open lysosomal Ca²⁺ channels\n\n**Predicted Experiment:** Live-cell imaging with GCaMP6 targeted to lysosomes vs. cytosol; measure simultaneous Ca²⁺ and cathepsin B release kinetics using matched FRET reporters (e.g., CatB activity sensor). Use CRISPRi knockdown of TRPML1 to test if Ca²⁺ release is required for TFEB activation and autophagy enhancement.\n\n**Confidence:** 0.72\n\n---\n\n## Hypothesis 2: Differential Calpain-Mediated Cleavage of Apoptotic vs. Autophagic Substrates\n\n**Mechanism:** Transient cathepsin release activates cytosolic calpains, which preferentially cleave pro-apoptotic proteins (BID, BAX) into inactive fragments, while autophagy machinery proteins remain intact or are cleaved into activating forms. This creates a temporary \"apoptosis-proofed\" state that permits autophagic flux.\n\n**Target:** CAPN1/CAPN2 (calpains), BID, BAX, AMPK\n\n**Supporting Evidence:**\n- Calpains cleave BID into pro-survival fragments that antagonize full-length BID function (PMID: 15068671)\n- Limited calpain activation can cleave BAX into an inactive form (PMID: 16103217)\n- Calpain-mediated AMPK activation links Ca²⁺ signaling to autophagy initiation (PMID: 21971070)\n\n**Predicted Experiment:** Isotope-coded affinity capture to map calpain cleavage substrates in trehalose-treated motoneurons; compare apoptotic (BID, BAX, caspases) vs. autophagic (AMPK, ULK1) cleavage patterns. Use calpain inhibitors (calpeptin) to determine if blocking calpain activity restores apoptosis sensitivity to trehalose.\n\n**Confidence:** 0.65\n\n---\n\n## Hypothesis 3: BAG3-Mediated Hsp70 Substrate Redistribution\n\n**Mechanism:** Trehalose induces Hsp70 and BAG3 expression, redirecting Hsp70 chaperone activity from inhibiting autophagy receptors (e.g., p62/SQSTM1 sequestration) toward maintaining lysosomal membrane integrity and preventing cytochrome c release. BAG3 simultaneously promotes autophagosome-lysosome fusion while inhibiting apoptosis initiation.\n\n**Target:** HSPA1A/Hsp70, BAG3, p62, cytochrome c\n\n**Supporting Evidence:**\n- BAG3 redirects Hsp70 from proteasomal to autophagic degradation (PMID: 25983032)\n- Hsp70 prevents Bax translocation to mitochondria and cytochrome c release (PMID: 12082527)\n- Trehalose upregulates Hsp70 as a general stress response (PMID: 21654180)\n\n**Predicted Experiment:** Co-immunoprecipitation of Hsp70 with BAG3 vs. p62 in trehalose-treated cells; measure cytochrome c release kinetics from mitochondria using targeted biosensors; BAG3 CRISPR knockout to determine if loss of BAG3 converts trehalose from pro-autophagic to pro-apoptotic.\n\n**Confidence:** 0.68\n\n---\n\n## Hypothesis 4: Cathepsin-Dependent Processing of Pro-Drug Enzymes into Autophagy Activators\n\n**Mechanism:** Trehalose-induced LMP releases cathepsin D, which specifically cleaves a cytosolic substrate (potentially pro-CTSD or an unidentified regulatory protein) into fragments that activate autophagy. These same fragments may degrade inhibitory proteins of apoptosis, creating parallel beneficial outcomes.\n\n**Target:** CTSD (cathepsin D), unidentified substrate \"X\"\n\n**Supporting Evidence:**\n- Cathepsin D can cleave and activate pro-autophagy proteins (PMID: 23716583)\n- Cathepsin D cleaves Bid into pro-survival fragments at different sites than caspases (PMID: 14517278)\n- Cathepsin D release correlates with autophagy in trehalose models (PMID: 30335591)\n\n**Predicted Experiment:** Activity-based protein profiling (ABPP) with cathepsin D-targeted probes to identify specific cleavage substrates unique to therapeutic LMP (vs. toxic LMP); mass spectrometry of cytosolic fraction before/after trehalose to identify candidate substrate X. Validate by expressing cleavage-resistant mutant of substrate X and testing if trehalose autophagy enhancement is lost.\n\n**Confidence:** 0.58\n\n---\n\n## Hypothesis 5: TFEB-Dependent Transcription of Lysosomal Biogenesis Genes Reduces LMP Toxicity Threshold\n\n**Mechanism:** TFEB activation by trehalose increases lysosomal biogenesis, expanding the lysosomal population. This creates a higher threshold for apoptosis—more lysosomes must permeabilize to release sufficient cathepsins for mitochondrial outer membrane permeabilization (MOMP), while the increased lysosomal mass accelerates autophagosomal degradation.\n\n**Target:** TFEB (TFE3), lysosomal V-ATPase, CTSD, ATP6V1H\n\n**Supporting Evidence:**\n- TFEB overexpression increases lysosome number and protects against proteotoxic stress (PMID: 29437794)\n- Increased V-ATPase activity enhances autophagic flux (PMID: 26387543)\n- Trehalose activates TFEB nuclear translocation (PMID: 30335591)\n\n**Predicted Experiment:** LysoTracker quantitation and TEM to measure lysosomal number before/after trehalose treatment; test if TFEB knockout or overexpression shifts the dose-response curve for trehalose-induced LMP vs. autophagy. Measure the \"lysosomal load\" threshold required for apoptosis activation using Bak/Bax double knockout cells.\n\n**Confidence:** 0.74\n\n---\n\n## Hypothesis 6: Selective PI3P Generation at Damaged Lysosomes Promotes Membrane Repair\n\n**Mechanism:** Trehalose-induced LMP creates \"damaged lysosome\" signals that selectively recruit PtdIns3P-generating machinery (PI3KC3 complex II) to initiate autophagosome formation at lysosomal membranes. This PI3P generation simultaneously recruits repair machinery (ESCRT-III) while excluding apoptotic initiators (Apaf-1, procaspase-9), directing the response toward repair rather than death.\n\n**Target:** PIK3C3/VPS34, PIK3R4/VPS15, CHMP2A (ESCRT-III), Apaf-1\n\n**Supporting Evidence:**\n- Damaged lysosomes recruit VPS34 complexes to generate PI3P for autophagy initiation (PMID: 29311636)\n- ESCRT-III machinery repairs permeabilized lysosomes (PMID: 29274069)\n- PIK3C3 complex II localizes specifically to damaged organelles (PMID: 30606815)\n\n**Predicted Experiment:** Live-cell imaging with GFP-2×FYVE domain (PI3P sensor) and mCherry-CHMP2A (ESCRT marker) at lysosomes after trehalose treatment; determine spatial and temporal relationship between PI3P generation, ESCRT recruitment, and autophagosome formation. Test if VPS34 inhibition (VPS34-IN1) or CHMP2A knockdown converts trehalose to toxic LMP.\n\n**Confidence:** 0.62\n\n---\n\n## Hypothesis 7: Metabolic Reprogramming Toward Glyceraldehyde-3-Phosphate Dehydrogenase Inhibition of Apoptosis\n\n**Mechanism:** Trehalose metabolism generates intermediates (particularly GAPDH activity modulators) that inhibit GAPDH nuclear translocation required for apoptosis. Meanwhile, trehalose-derived metabolites support ATP production needed for autophagy, creating a metabolic switch favoring survival.\n\n**Target:** GAPDH, HK2 (hexokinase II), VDAC1\n\n**Supporting Evidence:**\n- GAPDH nuclear translocation triggers apoptosis in neurodegeneration models (PMID: 28877451)\n- Trehalose metabolism engages the pentose phosphate pathway (PMID: 28122321)\n- Hexokinase II binding to VDAC1 prevents apoptosis initiation (PMID: 29478836)\n\n**Predicted Experiment:** Metabolomic profiling of trehalose-treated motoneurons to identify specific metabolic intermediates; test if GAPDH nuclear translocation is blocked by trehalose using nuclear/cytosolic fractionation; measure VDAC1-hexokinase II association as a proxy for mitochondrial protection. Use GAPDH overexpression or nuclear-targeting constructs to bypass trehalose protection.\n\n**Confidence:** 0.55\n\n---\n\n## Summary Table\n\n| # | Hypothesis | Primary Target | Confidence |\n|---|------------|----------------|------------|\n| 1 | Limited Ca²⁺ release without cathepsin efflux | TRPML1/calcineurin | 0.72 |\n| 2 | Differential calpain cleavage | CAPN1/2 | 0.65 |\n| 3 | BAG3-Hsp70 redistribution | HSPA1A/BAG3 | 0.68 |\n| 4 | Cathepsin D substrate processing | CTSD/\"substrate X\" | 0.58 |\n| 5 | TFEB-induced lysosome biogenesis | TFEB/TFE3 | 0.74 |\n| 6 | PI3P generation at damaged lysosomes | PIK3C3/VPS34 | 0.62 |\n| 7 | Metabolic reprogramming/GAPDH inhibition | GAPDH/HK2 | 0.55 |\n\n---\n\n**Recommended Priority Investigation:** Hypothesis 1 (Ca²⁺ vs. cathepsin kinetics) and Hypothesis 5 (TFEB-driven lysosome biogenesis) represent the most tractable approaches with available tools and directly address the mechanistic paradox. Combined temporal analysis of Ca²⁺ release, cathepsin activity, and TFEB nuclear translocation using high-content imaging would rapidly discriminate between these models.",
  "tokens_used": "2305",
  "persona_id": "persona-theorist"
}